How NAD+ fuels cellular energy and DNA repair

Every cell in your body needs NAD+. Production drops with age. Demand goes up. That gap is the longevity story.

TL;DR

NAD+ (nicotinamide adenine dinucleotide) is the cellular currency for turning food into energy and repairing DNA.
NAD+ levels fall with age while demand rises — the gap is one reason cells perform less well over time.
Precursors like NR and NMN can raise NAD+ in human studies. The longer-term clinical effect is still being researched.

What it is

NAD+ stands for nicotinamide adenine dinucleotide (in plain English: a molecule that shuttles electrons inside cells and shows up in hundreds of biological reactions). It is a coenzyme (in plain English: a helper molecule that proteins need to do their job). Every cell uses it. Take it away and the lights go out. NAD+ is also the fuel for a family of enzymes called sirtuins (in plain English: proteins that act like maintenance crew chiefs, switching cellular cleanup and repair on or off).

How it works

Think of NAD+ as cash in a wallet. Cells spend it every time they convert food to energy, fix a strand of damaged DNA, or signal a sirtuin to start a repair job. Healthy young cells get paid quickly and have a thick stack of bills. Older cells earn less and spend more — the wallet gets thinner. The thinner the wallet, the more often a cell has to choose between paying for energy production and paying for repair. Skipped repairs accumulate. That accumulation looks a lot like the wear pattern researchers describe as biological aging.

Who asks about it

People come to NAD+ from two directions. The first is the longevity podcast circuit — Sinclair, Huberman, and others have made NMN and NR household terms online. The second is post-COVID fatigue, where some researchers have flagged NAD+ depletion as a possible factor in slow recovery.

What the research says

Animal studies show that boosting NAD+ improves mitochondrial function (in plain English: how well cells produce energy), DNA repair, and several aging biomarkers (NIH PMC review, 2019). Human studies of NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) supplements consistently show they raise NAD+ levels in blood, with a generally well-tolerated safety profile across short studies (NIH PMC review, 2020). The harder question — whether higher NAD+ translates to longer healthspan in humans — is still in active study. Early human data is encouraging on energy and exercise metrics. The longevity signal will take more years to confirm.

What to know before considering it

NAD+ precursors are sold as supplements. Quality varies widely. NR is generally considered to have stronger safety data than NMN in published human studies. NAD+ IV drips are popular in wellness clinics but have less peer-reviewed support than oral precursors. Effects are subtle and slow — anyone promising dramatic short-term changes is overselling. A clinician should help calibrate, especially if you take other medications.

The Halftime POV

The NAD+ story is genuinely interesting. It is also early. The mechanism is real. The mouse data is striking. The human data is promising but not yet definitive. That is what honest longevity science looks like — worth understanding now, worth waiting on for big claims. We will write about this molecule the same way as the trials mature: in plain English, with the receipts, and without the hype.

Related reading:

FAQ

Q: What does NAD+ do? A: NAD+ is a coenzyme that helps cells convert food into energy and repair damaged DNA. It is involved in hundreds of cellular reactions every second.

Q: Why do NAD+ levels decline with age? A: Production slows and consumption rises. Inflammation, DNA damage, and metabolic stress all increase NAD+ demand as you age.

Q: Do NAD+ supplements actually raise NAD+ levels? A: Precursors like NR and NMN can raise blood NAD+ levels in human studies. Whether this translates to clinical longevity outcomes is still being researched.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.